[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100567709":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":23,"locations":31,"responsibleParty":44,"collaborators":47,"id":54,"slug":18,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":18,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":18,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":77,"whyStopped":18,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Peking University People's Hospital","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"Pralatrexate combined with Chidamide bridging allo-HSCT for Relapse\u002FRefractory PTCL patients","EXPERIMENTAL",[12],"Other: Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":18},"Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation","Drug: Pralatrexate, Chidamide\n\n1. Pralatrexate: 30 mg\u002Fm2 intravenously (IV) administered weekly in 6-week cycles. Chidamide: 20mg, twice a week in 3-week cycles (2 weeks on treatment, 1 week off treatment)\n2. After the 6-week therapy, the patients should receive PET\u002FCT evaluation.\n3. Patients would receive allo-HSCT if they could achieve at least PR after the first cycle of therapy. For the patients could not achieve a least PR after the first cycle of therapy, they should receive a second cycle of pralatrexate combined with chidamide. The interval between two cycles of pralatrexate combined with chidamide should be at least 1 week.\n4. After the second cycle of 6-week therapy, the patients should receive PET\u002FCT evaluation. Patients would receive allo-HSCT if they could achieve at least SD after the second cycle of therapy. For the patients could not achieve a least SD after the second cycle of therapy, they should receive other salvage therapies.",[9],null,[20],{"name":21,"affiliation":5,"role":22},"Xiaodong Mo","PRINCIPAL_INVESTIGATOR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":18,"email":28},"Xiaodong Mo, MD","CONTACT","8610-8832-6001","mxd453@163.com",{"name":25,"role":26,"phone":30,"phoneExt":18,"email":28},"8610-8832-4577",[32],{"facility":33,"status":18,"city":34,"state":18,"zip":18,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Peking University, Institute of Hematolgoy, Beijing,","Beijing","China",{"type":37,"coordinates":38},"Point",[39,40],116.39723,39.9075,{"lat":40,"lon":39},[43],{"name":21,"role":26,"phone":18,"phoneExt":18,"email":18},{"type":22,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"Xiao-Jun Huang","Director",[48,50,52],{"name":49,"class":6},"Ruijin Hospital",{"name":51,"class":6},"Wuhan TongJi Hospital",{"name":53,"class":6},"West China Hospital","100567709",false,"NCT06671717","Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory\u002FRelapsed Peripheral T-cell Lymphoma","Pralatrexate Combined With Chidamide Bridging Allogeneic Hematopoietic Stem Cell Transplantation for Refractory\u002FRelapsed Peripheral T-cell Lymphoma","Inclusion Criteria:\n\n* Patients fully understand the study, voluntarily participate in and sign on the informed consent;\n* Diagnosed by histopathology Peripheral T-cell lymphoma;\n* ECOG PS score 0 or 1;\n* Relapsed or Refractory Peripheral T Cell Lymphoma；\n* According to the 2014 version of the Lugano criteria for lymphoma, there must be at least one CT\u002FMRI measurable lesion (measurable lymph node diameter\\>1.5cm; measurable extranodal lesion diameter\\>1.0cm)；\n* Provided a written pathological\u002Fhistological diagnosis report during the screening period and agreed to provide tumor tissue sections or tumor\u002Flymph node tissue specimens for testing at the central laboratory;\n* Expected survival at least 12 weeks；\n* Agreed to receive treatment with Pralatrexate\n\nExclusion Criteria:\n\n* NK\u002FT-cell lymphoma;\n* Achieving CR or PR after induction chemotherapies without relapse;\n* Dysfunction of vital organs;\n* Serious history of autoimmune diseases and immunodeficiency, including: positive for human immunodeficiency virus (HIV) antibodies; Or other acquired or congenital immunodeficiency diseases; Or have a history of organ transplantation;\n* Unwilling to accept allogeneic hematopoietic stem cell transplantation;\n* Undergoing other clinical studies within a month;\n* Without donor for transplantation;\n* Allergies to similar drugs and excipients of the research drug","ALL","18 Years","65 Years",{"count":64,"type":65},25,"ESTIMATED","INTERVENTIONAL",[68],"NA","This is a multicenter, prospective study of Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation for Refractory\u002FRelapsed Peripheral T-cell Lymphoma",[71,72],"Relapsed Peripheral T-Cell Lymphoma","Refractory Peripheral T-Cell Lymphoma",[74,75,76],"Allogeneic hematopoietic stem cell transplantation","Pralatrexate","Remission status before transplantation","NOT_YET_RECRUITING","2024-11-04",{"date":80,"type":81},"2024-11-06","ACTUAL",{"date":83,"type":65},"2024-12",{"date":85,"type":65},"2027-07",{"name":5,"class":6},1]